Ikena Oncology, Inc. (NASDAQ:IKNA) Short Interest Up 34.1% in February

Ikena Oncology, Inc. (NASDAQ:IKNA) was the recipient of a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 154,100 shares, an increase of 34.1% from the January 31st total of 114,900 shares. Approximately 1.1% of the shares of the stock are sold short. Based on an average trading volume of 226,700 shares, the short-interest ratio is currently 0.7 days.

Analyst Ratings Changes

IKNA has been the topic of a number of research analyst reports. Wedbush reaffirmed a “neutral” rating and issued a $2.00 target price on shares of Ikena Oncology in a report on Monday, December 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 target price on shares of Ikena Oncology in a report on Monday, November 11th.

Ikena Oncology Stock Performance

Shares of IKNA stock opened at $1.29 on Tuesday. Ikena Oncology has a fifty-two week low of $1.22 and a fifty-two week high of $1.94. The company has a market cap of $62.25 million, a PE ratio of -1.05 and a beta of 0.48. The stock’s fifty day moving average price is $1.50 and its two-hundred day moving average price is $1.63.

Institutional Investors Weigh In On Ikena Oncology

Several hedge funds have recently modified their holdings of the company. BML Capital Management LLC lifted its holdings in Ikena Oncology by 23.6% during the 3rd quarter. BML Capital Management LLC now owns 723,288 shares of the company’s stock worth $1,251,000 after buying an additional 138,174 shares during the period. FMR LLC raised its position in shares of Ikena Oncology by 94.1% in the 3rd quarter. FMR LLC now owns 38,374 shares of the company’s stock worth $66,000 after acquiring an additional 18,607 shares in the last quarter. BBR Partners LLC raised its position in shares of Ikena Oncology by 550.0% in the 3rd quarter. BBR Partners LLC now owns 130,000 shares of the company’s stock worth $225,000 after acquiring an additional 110,000 shares in the last quarter. NEA Management Company LLC raised its position in shares of Ikena Oncology by 5.3% in the 3rd quarter. NEA Management Company LLC now owns 600,063 shares of the company’s stock worth $1,038,000 after acquiring an additional 30,013 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Ikena Oncology by 5.6% in the 3rd quarter. Geode Capital Management LLC now owns 271,026 shares of the company’s stock worth $469,000 after acquiring an additional 14,319 shares in the last quarter. Institutional investors and hedge funds own 75.00% of the company’s stock.

Ikena Oncology Company Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.